1000 E Main St, Indiana, United States, United States
Advertisements
Upcoming events at this venue
Indonesia Footwear Summit 2026
#_EVENTSTARTDATE
13 Apr - 15 Apr 2026, 5:00 am - 5:00 pm
The Indonesia Footwear Summit 2026, co-organized by Asosiasi Persepatuan Indonesia (APRISINDO) and ECV International, will be held in...
Argus Biofuels and Feedstocks Asia Conference, April 2026, Singapore
#_EVENTSTARTDATE
13 Apr - 15 Apr 2026, 8:00 am - 1:00 pm
In a time of rapid decarbonisation, supply chain disruption, and shifting regulations, you need more than just...
Military Robotics and Autonomous Systems | 13 - 15 April 2026 | London, United Kingdom
#_EVENTSTARTDATE
13 Apr - 15 Apr 2026, 8:00 am - 5:00 pm
A premier three-day conference on robotic and autonomous systems in military land operations. #MRAS2026 Purpose and Key...
Smart Water Systems 2026
#_EVENTSTARTDATE
13 Apr - 14 Apr 2026, 8:00 am - 6:00 pm
The primary goal is to examine cutting-edge technologies, explore the latest industry trends, and share best practices...
19th World Congress on Nursing Education & Health Care 2026
#_EVENTSTARTDATE
13 Apr - 15 Apr 2026, 9:00 am - 5:00 pm
For Next Year “19th World Congress on Nursing Education & Healthcare” is scheduled for April 13–15, 2026...
PUBLICHEALTH-2026
#_EVENTSTARTDATE
13 Apr - 15 Apr 2026, 9:30 am - 6:00 pm
PAGES conferences are excited to invite you to the upcoming International Conference on Public Health and Health...
Global Power Markets Conference at Four Seasons Hotel Las Vegas
#_EVENTSTARTDATE
13 Apr - 15 Apr 2026, 10:00 am - 5:00 pm
The Global Power Markets Conference returns at a pivotal moment for the energy sector. With national energy...
8th Neuroimmunology Drug Development Summit
#_EVENTSTARTDATE
14 Apr - 16 Apr 2026, 9:00 am - 5:00 pm
Neuroimmunology is entering a defining moment. With the $470M buyout of Vigil's TREM2 asset, Ventus' NLRP3 inhibitor...
8th Neuroimmunology Drug Development Summit at Boston, MA
#_EVENTSTARTDATE
14 Apr - 16 Apr 2026, 9:00 am - 5:00 pm
Neuroimmunology is entering a defining moment. With the $470M buyout of Vigil’s TREM2 asset, Ventus’ NLRP3 inhibitor...